NEW YORK, August 23, 2026, 3:12 p.m. EDT
- NANO Nuclear’s $580 million liquidity equals 57% of Friday’s market value.
- Shares fell 4.1% last week while uranium producer Cameco gained 3.8%.
- A $373 million unused ATM authorization remains a dilution overhang.
NANO Nuclear Energy Inc. NASDAQ:NNE ended Friday with roughly $1.01 billion of market value. Its $580 million liquidity position covers 57% of that figure.
That leaves investors assigning about $432 million to the operating platform, net of cash and short-term investments. The calculation is preliminary and excludes other assets and liabilities.
The balance sheet did not stop a 4.1% weekly decline. Shares closed at $18.85, even after a 3.4% Friday rebound.
| Nuclear exposure | Ticker | Aug. 14 close | Aug. 21 close | Weekly move |
|---|---|---|---|---|
| Cameco | NYSE:CCJ | $97.74 | $101.43 | +3.8% |
| NuScale Power | NYSE:SMR | $9.39 | $9.40 | +0.1% |
| Centrus Energy | NYSE:LEU | $190.15 | $183.95 | -3.3% |
| NANO Nuclear | NASDAQ:NNE | $19.66 | $18.85 | -4.1% |
| Oklo | NYSE:OKLO | $44.38 | $42.09 | -5.2% |
Friday’s split was telling. Fuel producer Cameco Corporation NYSE:CCJ rose 6.1%. Pre-commercial reactor developers remained weaker over the week.
Short sellers have earned an estimated $2.1 billion across NANO, NuScale and Oklo over the past year, S3 Partners data showed. Their combined value has fallen $30.3 billion from last October’s peak.
| Valuation bridge | Amount | Investor read-through |
|---|---|---|
| Friday market value | $1.012 billion | 53.70 million shares × $18.85 |
| Cash and short-term investments | $580.0 million | 57.3% of market value |
| Value net of liquidity | $432.2 million | Preliminary equity-value bridge |
| Nine-month operating cash use | $18.7 million | 3.2% of liquidity |
| Nine-month net loss | $25.8 million | Business remains loss-making |
Chief Executive James Walker called liquidity a “significant strategic advantage” in the quarterly update. It funds licensing, reactor work and acquisitions without immediate financing pressure.
Cash came with dilution. Outstanding shares rose 29% from August 2025. The company also retains $373.25 million of capacity under its at-the-market program.
No additional ATM shares were sold from July 1 through the August 10 filing date. That pause helps. The authorization still gives management room to issue stock later.
| Execution marker | Status | What remains |
|---|---|---|
| KRONOS MMR construction permit | NRC accepted application for review | Technical review and approval |
| First reported revenue | $214,042 after STS acquisition | Scale logistics operations |
| HALEU supply | Non-binding Quadrant MOU | Convert framework into contracts |
| Investor conference | Barclays on Sept. 8 | Updated commercialization detail |
The revenue base remains tiny. Secured Transportation Services generated $214,042 between its May acquisition and quarter-end. Four customers supplied 95% of that revenue.
KRONOS carries the larger valuation case. The Nuclear Regulatory Commission accepted its University of Illinois construction-permit application in May. Approval and deployment remain years away.
Tuesday’s HALEU agreement adds another option. NANO and Quadrant Nuclear Industries will explore long-term fuel supply. The memorandum is non-binding and sets no purchase volume.
| Analyst or consensus | Date | Recommendation | Target | Vs. $18.85 |
|---|---|---|---|---|
| Alliance Global Partners | July 27 | Buy | $46 | +144.0% |
| Truist Securities | July 14 | Hold | $22 | +16.7% |
| Benchmark | June 26 | Buy | $45 | +138.7% |
| Roth/MKM | June 17 | Buy | $45 | +138.7% |
| S&P Global poll, 7 analysts | Aug. 21 snapshot | Buy | $40.83 average | +116.6% |
Analysts see large upside, but the range reflects long timelines. Truist’s $22 target sits only 16.7% above Friday’s close. The consensus implies more than a doubling.
Risks: Licensing delays, reactor redesigns and customer concentration could reduce value. Future ATM sales may dilute holders, even with ample liquidity today.
The near-term investment case is therefore a balance-sheet discount, not reactor earnings. Cash limits financial stress. It does not shorten the commercialization clock.
Related articles: NASDAQ:NNE
